177/179 cases (98%). Positive sentinel lymph node was identified in 26/177 patients (14.7%). In node positive patients the thickness of the primary tumour was significantly greater than that of node negative ones (p<O.OOOOI). Patients with micrometastases had significantly poorer symptom-free and overall survival by the Mantel-Cox test than those of the other group (p=O.OOOI and p=0.0007 respectively). Comparison of the tumor thickness and positive SLN by discriminance analysis, yielded 81.7% and 79.9%, respectively for correct classification rates. Based on our study and data from the literature, we suggest SLN-positivity as equally strong poor prognosis factor for skin melanoma as the tumor thickness.
Introduction
Involvement of regional lymph nodes is one of the most significant prognostic factor in malignant melanoma affecting the selection of the therapy.6,9,10 The sentinel lymph node (SLN) biopsy is a minimally invasive method that helps to evaluate the status of the lymph node region of the primary tumor. Its principles were described by Cabanas in penis carcinoma 5 and the patent blue technique for its clinical use in malignant melanoma was worked out by Morton somewhat later, in the 90'S.12 With the advent of this methodology the decade long dispute about elective block dissection could finally be settled. The applica-tion of radioisotopes 2 raised the diagnostic accuracy from 85-90% to 95_99%.1,12,13 Pathological analysis of the SLN specimen raised several new questions regarding the definition of tumor metastasis, but the accepted guideline defines it as a tissue of the size equal or larger than 2 mm. 3 ,19 This recommendation does not accept smaller sized metastasis to affect clinical decisions. Here we have analysed the clinical and prognostic significance of SLN surgery in a large group of skin melanoma patients followed for 5 years.
Patients and Methods
We have performed SLN surgery on 179 patients treated at the Department of Dermatology, National Institute of Oncology, Budapest during the period from November 1997 to September 2002. Most of the primary malignant melanomas of the skin represented moderate to high risk for dissemination and the rest were thin melanomas show- Presence of metastasis in the sentinel lymph node was verified in 26 cases (14.7%). In two patients the subsegment block dissection was proved to be positive (7.6%). The clinical and pathological sentinel node negative and positive patient's characteristics are given in Table 1 . Data indicate that SLN positive melanoma occurred more frequently on the lower extremities and are more frequently of the acrolentiginous type. Histological signs of spontaneous regression were noted in 46 cases (25.9%). However, only in 1/26 sentinel node positive patient was found to have a regressing primary tumor (3.8%).
The follow up period ranged from 1-59 months (mean 22,1). In 18/151 sentinel node negative patients progression developed (11.9%). Lymph node recurrence in the SLN region was detected in 4 cases (false negative ratio: 4/30 =13.3%). Three patients developed local and in-transit metastasis (3/151 = 1,9%), while hematogenic metastasis was found in 11 patients (11/151 = 7,3%).
In the SLN positive group 11/26 (42.3%) patients experienced progression. Lymph nodes beyond the SLN region were found to be positive in one patient and in transit metastasis in another. Hematogenic dissemination was demonstrated in 8/26 patients (30.8%).
In the group of SLN negative patients the average tumor thickness was 1,9 mm in contrast to the 4,1 mm thickness with the node positive patients (F-test, p<O,OOOOl). The average tumor thickness in patients showing SLN negativity and tumor progression (3.3 mm) was smaller compared the tumors where SLN was positive (6.0 mm, p=0,057, Ftest). Finally, the thickness of the primary tumors in SLN positive patients without progression was significantly smaller (3.0 mm) compared to progressing tumors (6.0 mm, p<O.Ol, F-test). ing signs of spontaneous regression. The sentinel lymph node surgery was combined with wide excision (1-2 cm margins) of the primary malignancy. Patients who had been operated in an other institution underwent SLN biopsy 1-2 months after primary tumour excision. The clinical details of the patients and the pathological characteristics of their tumours are summarised in Table 1 . The SLN biopsy was carried out with the double labelling (99mTc -human colloid serum albumin and patent blue) method combined with dynamic lymphoscintigraphy. Surgery was conducted under general anaesthesia and in a few cases under local anaesthesia. The histological evaluation of the sentinel lymph nodes was performed on serial sections according to ADASP recommendations. 3 ,19 Micrometastasis equal or larger than 2 mm was determined. Smaller sized groups of tumor cells were reported but not considered metastatic SLN. For the immunohistochemical detection of melanoma cells S-100, HMB-45, Melan-A was used in the case of suspected micrometastases. Diagnosis of positive SLN was followed by regional block dissection within a week.
Patients with melanoma of >1 mm thickness or those showing signs of regression were given low dose interferon-a2 (3-5 ME, 3 times a week) or BCG therapy, at a 6 weekly basis. In harmony with our melanoma protocol patients were regularly tested by physical and imaging examinations (chest X-ray, abdominal ultrasonography and bone scan, CT and MRI, when needed).
Data have been analysed by F-test, the Mantel-Cox regression model and by discrimination analysis. 4 In the National Institute of Oncology we have been performing sentinel lymph node biopsy for 5 years. 8 The method has proved in our handsto have 98% diagnostic accuracy. Sentinel lymph node positivity in skin melanoma was found in 14.7% of the patients. Both rates are in harmony with literature data which state that the ratio of sentinel lymph node positive patients may range from 10 to 40%. 6, 15, 16 At present, the sentinel lymph node status is considered the most important prognostic factor in melanoma. Analysis of the clinical data of 4218 patients who had undergone sentinel lymph node surgery demonstrated that the most essential predictor of sentinel lymph node positivity was the thickness of the primary tumour. 7 In this respect melanomas showing signs of spontaneous regression may be exceptions even though the prognostic significance of regression characteristics is rather controversial. We have to mention however, that it is the sentinel lymph node examination that may yield useful information about the biological significance of the regression features.
ll Our own observations are also in line with the statement that the primary tumors of the SLN positive patients are significantly thicker than those of the SLN negative ones. On the other hand, thickness of the primary tumor is still a strong indicator for tumor progression, since the SLN positive patients whose tumor progressed showed significant1y greater thickness than those without dissemination.
In our patient group regression signs were identified only in one of the SLN positive patients. However, we think that because of the rather uncertain clinical course of thin, regressing tumours, SLN surgery does represent an important source of information from the point of view of clinical staging.
The disease-free and overall survival rates of the SLN positive patients were significantly poorer compared to SLN negative ones. The question arises whether all patients benefit from early block dissection. Some authors suggest that one should make the intervention depending on the extent of the involvement of lymph nodes. Based on our own results we support this notion. 6 ,8 There is an ongoing debate on the relative value of the Breslow thickness and SLN positivity in the prediction of disease outcome in melanoma. The discriminance analysis of our data found no significant differences between the two parameters indicating that both factors should be included in the prediction of the outcome of the disease.
Based on own experience and internationally accepted gUidelines 4 as well as recommendations of the Hungarian Consensus Conference on Melanoma we recommend the sentinel lymph node surgery in all cases of primary malignant melanoma except those of absolute good prognosis' i.e. <1 mm thick, not ulcerated, does not show signs of regression and depth of invasion <Clark level III. In such cases surgery seems unnecessary. Furthermore, The disease-free (DFS) and overall survival (OS) rates of the sentinel node negative and positive patients were calculated by the method of Kaplan-Meier (Figures, 1,2 , respectively). For each parameter the Mantel-Cox model disclosed significant difference in favour of the sentinel node negative patients (p=O,OOO 1 and p=0,0007, respectively).
Last, we have compared the predictive value of the Breslow thickness to the SLN positivity for OS by discriminance analysis. These studies indicated that both factors have a comparably high poor prognosis predictive value for OS in case of skin melanoma (Breslow=81.7%, SLN+=79.9%).
Although the clinical benefit of sentinel lymph node dissection is still a controversial matter to some authors, 6 the fact, that the sentinel lymph node status has become an integral part of the new melanoma staging and has ben introduced into the clinical practice of surgical manage- in cases of ulcerated, >4 mm thick tumours, it is not worth performing SLN biopsy either because prognosis is very poor, independent of the result of the intervention.
